Bridging the treatment gap in infant medulloblastoma: Molecularly informed outcomes of a globally feasible regimen.
暂无分享,去创建一个
P. Northcott | V. Ramaswamy | U. Bartels | E. Bouffet | F. Lubieniecki | Kyle S. Smith | Lorena V. Baroni | Ayala Heled | D. Alderete | C. Sampor | C. Rugilo | Adriana Gonzalez | G. Lamas
[1] F. Gilles,et al. Excellent Outcome of Young Children with Nodular Desmoplastic Medulloblastoma Treated on "Head Start" III: A Multi-Institutional, Prospective Clinical Trial. , 2020, Neuro-oncology.
[2] W. Whitehead,et al. Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Souweidane,et al. Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221). , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Derek W. Yecies,et al. Molecular correlates of cerebellar mutism syndrome in medulloblastoma. , 2019, Neuro-oncology.
[5] C. Hawkins,et al. Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost , 2019, Cancer.
[6] V. Ramaswamy,et al. Clinical and pre-clinical utility of genomics in medulloblastoma , 2018, Expert review of neurotherapeutics.
[7] M. Remke,et al. Infant medulloblastoma — learning new lessons from old strata , 2018, Nature Reviews Clinical Oncology.
[8] Martin Sill,et al. Heterogeneity within the PF-EPN-B ependymoma subgroup , 2018, Acta Neuropathologica.
[9] B. Morland,et al. Sodium Thiosulfate for Protection from Cisplatin‐Induced Hearing Loss , 2018, The New England journal of medicine.
[10] David T. W. Jones,et al. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. , 2018, The Lancet. Oncology.
[11] David T. W. Jones,et al. Molecular characterization of medulloblastomas with extensive nodularity (MBEN) , 2018, Acta Neuropathologica.
[12] M. Chintagumpala,et al. Attention, processing speed, and executive functioning in pediatric brain tumor survivors treated with proton beam radiation therapy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[13] K. Walsh,et al. Intellectual Outcome in Molecular Subgroups of Medulloblastoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Elizabeth M. Wells,et al. Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High‐Dose Chemotherapy , 2016, Pediatric blood & cancer.
[15] A. V. von Bueren,et al. Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy. , 2015, European journal of cancer.
[16] Douglas C. Miller,et al. Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group. , 2015, Pediatric neurology.
[17] Michael D. Taylor,et al. Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Volker Hovestadt,et al. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort , 2014, Acta Neuropathologica.
[19] H. Christiansen,et al. Postponed is not canceled: role of craniospinal radiation therapy in the management of recurrent infant medulloblastoma--an experience from the HIT-REZ 1997 & 2005 studies. , 2014, International journal of radiation oncology, biology, physics.
[20] Toshihiro Kumabe,et al. Cytogenetic prognostication within medulloblastoma subgroups. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] David T. W. Jones,et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. , 2013, The Lancet. Oncology.
[22] Volker Hovestadt,et al. Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays , 2013, Acta Neuropathologica.
[23] Scott L. Pomeroy,et al. Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.
[24] Douglas C. Miller,et al. Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma: Children's Oncology Group study P9934. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.
[26] T. Pietsch,et al. Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. , 2011, Neuro-oncology.
[27] D. Figarella-Branger,et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Grill,et al. Medulloblastoma in young children , 2010, Pediatric blood & cancer.
[29] C. Hawkins,et al. Impact of radiation avoidance on survival and neurocognitive outcome in infant medulloblastoma , 2009, Current oncology.
[30] D. Frappaz,et al. High‐dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy , 2007, Cancer.
[31] R. Mulhern,et al. Radiation dosimetry predicts IQ after conformal radiation therapy in pediatric patients with localized ependymoma. , 2005, International journal of radiation oncology, biology, physics.
[32] Douglas C. Miller,et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] R. Mulhern,et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] D. Frappaz,et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. , 2005, The Lancet. Oncology.
[35] T. Pietsch,et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. , 2005, The New England journal of medicine.
[36] P. Duffner. Long-Term Effects of Radiation Therapy on Cognitive and Endocrine Function in Children With Leukemia and Brain Tumors , 2004, The neurologist.
[37] W. Reddick,et al. Predicting intellectual outcome among children treated with 35-40 Gy craniospinal irradiation for medulloblastoma. , 2003, Neuropsychology.
[38] A. Kiltie,et al. Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old. , 1997, Medical and pediatric oncology.
[39] M E Cohen,et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. , 1993, The New England journal of medicine.